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A complex individual patient simulation model (UKPDS Outcome Model version
1.3) was used with quality adjusted life years (QALY) and cost of complications as
model outputs. To reduce 1st-order uncertainty, 1000 patients were simulated for
each input combination selected. ANN simulation meta-models using a sample of
200 individual runs were developed and cross-validated to approximate the origi-
nal simulation as these do not require any specific input-output functional rela-
tionship and can handle any number of input parameters. Performance was com-
pared with a Gaussian Process (GP) meta-model, and a valid and better predictive
meta-model was then used for PSA. RESULTS: From ANN meta-models, the mean
absolute percentage error (defined as positive difference between the predicted
and true output divided by the range in true output) was 3.8 % for costs and 1.4% for
QALYs compared with 5.1% and 2.1% in GP meta-models. The distribution of errors
was approximately symmetrical around zero meaning that mean costs and QALYs
for an intervention are unlikely to be affected by the small inaccuracies associated
with ANN approximations. CONCLUSIONS: ANN produces better predictive capa-
bility than GP meta-models in estimating costs and QALYs from the UKPDS out-
come model. A PSA carried out using the ANN meta-model demonstrated the po-
tential for ANN in analysing complex health economic models.
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A CHOICE THAT MATTERS: COMPARING METHODS OF DATA SYNTHESIS IN
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OBJECTIVES:Different methods of meta-analysis on model parameters can lead to
different outcomes of cost-effectiveness (CE) modeling. As the “true” CE is un-
known, it is unclear which method performs best. We compared different methods
of meta-analysis with regards to the underlying “true” CE outcome. METHODS: In
a simulation study we constructed two patient populations and their treatments
(“truth”): a chronic disease with events and a progressive lethal disease. We drew
trials from these populations, comparing two treatments, varying the number of
trials, trial sizes and between-study heterogeneity in scenarios. From each trial
utilities, transition and event probabilities, risk-differences and log-risk-ratios
were estimated. These parameters were synthesized using frequentist fixed-ef-
fects (FFE) and random-effects (FRE), Bayesian fixed-effects (BFE) and random-ef-
fects (BRE) models. A CE model was filled and probabilistic sensitivity analysis was
performed. We repeated this trial sampling, leading to 1000 sets of health economic
outcomes for each scenario. We compared methods of meta-analysis on bias and
coverage, the percentage of draws that the “true” outcome lies in the confidence
interval. RESULTS: Even in the most heterogeneous scenario, biases were limited
to approximately 5%, and similar for all methods, but small biases in individual
treatment arms occasionally led to biases up to 30% in the difference between
arms. FFE models consistently have lower coverage than BFE. With homogeneous
trials, all methods have coverage above 80% for all outcomes. BRE has coverage
higher than 99% for all outcomes, regardless of heterogeneity. With heterogeneity,
RE methods perform better than FE and FRE has a lower coverage compared to BRE.
All methods, even with heterogeneous trials, have 100% coverage around the ICER.
CONCLUSIONS: BFE or BRE models are preferred in all situations, as they are more
conservative. However, insight in the real level of heterogeneity is important, as
using BRE without heterogeneity will overestimate uncertainty.
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THE POWER OF ASSUMPTIONS
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OBJECTIVES: To develop a method which increases the potential to find statisti-
cally significant differences in costs and effects when a trial is powered using a
dichotomous outcome. METHODS: An example is used of a trial assessing an in-
tervention to prevent late pain. Treatment is expected to increase the percentage of
pain-free patients from 85% to 92%, giving a power of 80% with 500 patients. Using
EQ-5D as outcome decreases the power to 40%. We improve on this by deriving
T-tests in which the following assumptions are taken into consideration: 1. quality
of life with pain (8% vs 15%) is identical in both arms 2. quality of life without pain
(85% vs 92%) is identical in both arms Alternatively, we use a Bayesian approach
assuming that the differences between arms follow normal distributions with
mean zero and varying precision. Using simulations the frequentist and Bayesian
approach are linked and it is analysed to what extent the results depend on the
base line probabilities. RESULTS:Making both assumptions increases the power to
80% as in the binary assessment. Applying assumption 1 increases the power with
only 2%, applying assumption 2 increases it to almost 80%. When assuming that
the outcome is 44% versus 56% instead of 85% vs 92% both assumptions contribute
to the power approximately equally. The Bayesian model coincides with the as-
sumptions from the frequentist approach when the precision is set to the extremes
(zero or infinity). Between these it offers a flexible approach where the road from
one extreme to another is defined by cumulative normal distributions on the log of
the squared root of the precision. CONCLUSIONS: Traditional approaches may
disregard common sense. Building this into the analysis and the assessment of the
data will decrease suggested uncertainty and may decrease the need for large
patients numbers.
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OBJECTIVES: The use of registry databases and indirect comparisons has be-
come important in health economic evaluations. Lack of randomization could
lead to selection bias due to pretreatment differences between patients. To
control for selection bias, the propensity score method (PS) (Rosenbaum & Ru-
bin, 1983) is often applied. However, average treatment effects can vary within
different subgroups. It is yet unclear how to perform subgroups analyses when
the propensity score method is applied. METHODS: A Monte Carlo simulation is
conducted to test the performance of eight different forms of the PS in subgroup
analyses. The PSs differ in whether the variables included in the PS were indicators
of the subgroup and were related to treatment assignment, to outcome or related to
both assignment and outcome. Furthermore the PS is estimated in two ways, pri-
mary on treatment assignment only and secondly on a combination of the treat-
ment assignment and subgroup variable. These PSs were used as adjustment in a
regression model. Simulations are accomplished for 18 different settings varying
sample size, correlation between independent variables and correlation between
independent variables and subgroups. RESULTS: The PS without inclusion of the
variable for subgroups, but with inclusion of variables related to outcome, is the
most appropriate. The PS should be included as a covariate in a regression model
together with the variable for subgroups as covariate, where the PS is based on
treatment assignment only. Larger sample sizes gave less biased results, while a
higher correlation between the independent variables resulted in more biased es-
timates of the treatment and subgroup effect. Correlation between the indepen-
dent variables and the subgroup variable did not lead to biased results.
CONCLUSIONS: The results show the feasibility and validity of the PS in subgroups
analyses when analyzing registry databases and indirect comparisons in economic
evaluations.
PODIUM SESSION I:
LATEST INSIGHT IN THE ESTIMATION OF PRODUCTIVITY COST: BETTER
DESCRIBING THE SOCIETAL VALUE
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OBJECTIVES:Mood disorders are associated with a high societal cost, mainly due to
productivity loss and in particular presenteeism. The latter should therefore be
measured with the most appropriate tool. The objective is to review the use of ten
instruments in mood disorders and to provide recommendations about the most
appropriate instruments according to the situation. METHODS: A systematic re-
view was conducted using PubMed focusing on ten instruments: Endicott Work
Productivity Scale (EWPS), Health & Labour Questionnaire (HLQ), WHO Health and
Work Performance Questionnaire (HPQ), Health and Work Questionnaire (HWQ),
Lam Employment Absence and Productivity Scale (LEAPS), Sheehan Disability Scale
(SDS), Stanford Presenteeism Scale (SPS), Work and Health Interview (WHI), Work
Limitation Questionnaire (WLQ) and Work Productivity and Activity Impairment
(WPAI). Study characteristics and major results (by symptom level, by treatment
arm, correlation to other scales and use of monetisation) were extracted. RESULTS:
Twenty-nine studies (21 observational studies) were identified. No studies in mood
disorders were retrieved for two scales (HLQ and HWQ). SDS, WLQ and HPQ were
the most commonly used instruments. Most scales demonstrated higher presen-
teeism in patients with symptoms of mood disorders than in patients without.
LEAPS, SDS and WLQ showed increased presenteeism with increasing severity of
disease. Few studies reported results on presenteeism by treatment and no be-
tweentreatment differences were generally observed. Good correlations between
presenteeism instruments and clinical or quality of life scales were reported. Only
three studies converted results from presenteeism scales into monetary units.
CONCLUSIONS: Limited evidence exists to compare the performance of presentee-
ism scales in mood disorders. Recommendations for inclusion of a presenteeism
tool should be driven by theoretical arguments (ease of administration, amenabil-
ity to monetisation) and the study type. Future research should focus on the re-
sponsiveness demonstration and the evaluation of the impact of mood disorders
on self-reported assessment.
PC2
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OBJECTIVES: Many health economists consider applying the friction cost method
to estimate the productivity costs, but lack practical data and tools to apply the
method. This study aims to provide estimates for length of the friction period, cost
per working hour/day lost and friction costs for several European countries.
METHODS: Using national aggregate stock and flow time series data on vacancies,
we; 1) estimate vacancy durations for several European countries in order to esti-
mate the length of friction period, and 2) examine estimated vacancy durations
with unemployment and vacancy rates using regression analysis in order to check
the validity of estimated durations. Data for the price component for each country
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on hourly labour costs is used for productivity costs per working day/hour.
RESULTS:Vacancy durations estimated in 2009 for The Netherlands, Belgium, Ger-
many, France, the UK, Norway and Sweden range between 40-80 days. Regression
analysis of the vacancy durations shows that, there is a strong negative relation-
ship between vacancy durations and unemployment rates. When unemployment
increases, vacancy durations and hence friction period decline. We also find that
an increase in the vacancy rate (the ratio of the stock of vacancies to total labor
force) has a positive effect on vacancy durations which can be explained by the
congestion provoked by the increase in the number of vacancies competing in the
labor market.CONCLUSIONS:This paper provides estimates on vacancy durations,
friction periods and the price component in order to calculate the friction costs. For
seven European countries, we present empirical estimates to use the friction cost
method in a practical way which can improve more uniform analysis of productiv-
ity costs in economic evaluations of diseases. Our regression results confirm the
validity of estimated vacancy durations which are necessary to calculate the length
of friction period and friction costs.
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THE HUMAN CAPITAL APPROACH AND FRICTION COST APPROACH
Hanly P, Timmons A, Walsh P, Sharp L
National Cancer Registry Ireland, Cork, Ireland
OBJECTIVES: Productivity costs constitute a substantial proportion of the total
societal costs associated with cancer. Cancer patients may leave the workforce
permanently post-diagnosis, take time off during treatment and/or return to work
with reduced hours or die prematurely; the associated productivity costs have
rarely been considered. We applied the dominant human capital approach (HCA)
and the emerging friction cost approach (FCA) to estimate breast and prostate
cancer productivity costs in Ireland in 2008. METHODS: Data from a survey of
breast and prostate cancer patients (n358) was combined with population-level
survival estimates (from the population-based National Cancer Registry) and a
national wage dataset to calculate costs of temporary disability (cancer-related
work absence), permanent disability (workforce departure, reduced working hours)
and premature mortality, using the HCA and FCA. Sensitivity analyses were con-
ducted for key parameters: GNP growth and discount rates for HCA and friction
period and labour elasticity for FCA. RESULTS: According to the HCA, productivity
costs per person amounted to €193,425 for breast and €109,154 for prostate cancer.
FCA per person costs were €8103 for breast and €8205 for prostate cancer. The HCA
generated higher costs for younger patients (breast cancer) due to greater lifetime
earning potential. In contrast FCA resulted in higher productivity costs for older
male patients (prostate) commensurate with higher earning capacity over a shorter
time period. Reduced working hours post-cancer was a key driver of total HCA
productivity costs. HCA costs were sensitive to assumptions about discount and
growth rates. FCA costs were sensitive to assumptions about the friction period.
CONCLUSIONS: This study highlights the importance of choosing the correct val-
uation method for chronic long-term illnesses such as cancer, being explicit about
assumptions, and considering a range of cost sub-components, including those
due to reduced working hours.
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OBJECTIVES: The aim of this study was to estimate the impact of pandemic
Influenza A H1N1/2009 in terms of patient’s health care services utilization,
work absenteeism and associated costs. METHODS: Longitudinal, descriptive,
multi-centre study of in- and outpatients with confirmed diagnosis of influenza A
H1N1/2009 in Spain. Sociodemographic and clinical characteristics were gathered
together with health and social resources use, at the admission or primary visit,
and also after recovery. Cost analyses were conducted under a social perspective,
incidence focus and with a temporal horizon of 3 months. Unit cost of resources
was imputed to calculate the mean cost by inpatient and outpatient. A sensitivity
analysis with variations was conducted (Monte Carlo simulation). RESULTS:A total
of 172 inpatients and 224 outpatients were included, 20% and 30% of whom, re-
spectively, were under 17 years old; 12% of inpatients were at ICU, 7.8 (SD3.7)
days, on average, and stayed in general wards for 9.6 (SD7.7) additional days. The
rest of inpatients had a mean hospitalization length of 5 (SD4.4) days. The most
frequently used ambulatory health resource was the primary care medical assis-
tance; 43.8% of inpatients and 66.1% of outpatients were employed, of whom 100%
(inpatients) and 91.7% (outpatients) went on sick leave. Absenteeism length was of
30 (SD20.7) days for inpatients and 9 (SD6.3) for outpatients. Caregivers of 21.7%
of the inpatients also led work absenteeism, as well as the 8.5% of those of outpa-
tients. The proportion of indirect cost for general-ward-inpatients was 30%. This
percentage ascended to 77% in the case of outpatients. The mean costs per inpa-
tient were €6,236 (CI95%1,384–14,623) and €940 (CI95%66–3,064) per outpatient.
CONCLUSIONS: Hospitalizations represents the highest economic cost, together
with work absenteeism. Since only a marginal proportion of influenza cases are
hospitalized, productivity losses emerge as the most important impact of the dis-
ease.
PODIUM SESSION I:
IN-DEPTH STUDIES ON DIFFERENCES AND OPPORTUNITIES IN PRICING AND
MARKET ACCESS
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OBJECTIVES: This study evaluated several recent drug launches in Rheumatoid
Arthritis (RA) to determine which factors contribute to Health Technology Ap-
praisal (HTA) outcomes. METHODS: We reviewed the appraisals of RA drugs
launched in the last five years by the following HTA agencies: England (NICE),
Scotland (SMC), Sweden (TLV), France (HAS), Spain (CAHTA/CANM) and The Neth-
erlands (CVZ). We analysed the proportion of recommended, restricted and not
recommended appraisals and the reasons for these decisions. A subsequent anal-
ysis of the evidence and arguments developed in the appraisal by the HTA agency
was performed. We classified them as clinical, economic, humanistic or social, in
addition we analysed the outcome by country and drug. RESULTS: The listed HTA
agencies issued a total of 25 appraisals (first appraisal, indication expansion and
re-appraisal) for the 4 drugs analysed (certolizumab, golimumab, tocilizumab and
abatacept). There were 9 recommendations for use (36%), 13 restricted use deci-
sions (52%) and 3 decisions to not recommend for use (12%). In 96% of the cases, the
study design (population, add-on vs. monotherapy, duration of trials, comparators
etc.) were systematically quoted as the primary reason for the HTA agency deci-
sion. In 44% of these cases, in addition to design issues, the lack of convincing
health economic data was mentioned. The reasons for favourable recommenda-
tions were 100% clinical and 56% economic, for restricted 100% clinical and 31%
economic and in case of non-recommendation 67% clinical and 67% economic.
CONCLUSIONS: The primary reason for restriction and non-recommendation are
clinical design issues. Consequently it is recommended that manufacturers incor-
porate payer’s expectations in their development plan early enough to influence
trial design and to collect robust health economic evidence.
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OBJECTIVES: The recent UK value-based pricing (VBP) consultation proposes that
burden of illness, therapeutic improvement/innovation and wider societal benefits
are evaluated in addition to cost-effectiveness. This study explored attitudes
among industry, academia and UK National Health Service (NHS) stakeholders to
the proposed VBP framework, with a focus on how to define the burden of illness
component. METHODS: Relevant literature was identified via a manual search to
assess the use of VBP methodologies in other countries and potential burden of
illness (BOI) criteria. In-depth, semi-structured 40-minute telephone interviews
were then undertaken with 20 experts identified in UK academic centres, the phar-
maceutical industry and the NHS. Discussions explored perspectives on VBP and in
particular how to define and evaluate BOI. RESULTS: Proposed definitions for BOI
varied significantly. Industry representatives wanted the flexibility to use a broad,
variable set of criteria, while academic and NHS stakeholders wanted practical,
consistent evaluation criteria with the emphasis on ensuring benefits are not ‘dou-
ble-counted’. Stakeholder input was used to develop a framework for assessing BOI
comprising disease severity, quality of life impact, treatment availability and per-
formance of existing treatments. Qualitative grading scales for each of the criteria
were proposed. While each stakeholder group broadly endorsed VBP objectives, the
research highlighted various concerns regarding its implications. In particular, the
need for clear government policy and guidance, further development of acceptable
evaluation methodologies (including criteria weightings), and enhanced pharma-
ceutical development processes to ensure evidence of sufficient quality is gener-
ated to support evaluation of product value (both at launch and over time).
CONCLUSIONS: There appears to be sufficient common ground to develop a BOI
assessment framework that is acceptable to both industry and NHS stakeholders.
We propose a relatively simple model that could form the basis for further research
and discussion, with special attention to addressing the implementation chal-
lenges.
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OBJECTIVES: The Pharmaceutical Market Restructuring Act (AMNOG) came into
action in Germany January 2011 with the aim of containing rising health care
expenditure, notably by introducing mandatory benefit assessments and price ne-
gotiation for all new innovative pharmaceuticals. The impact of the reform for the
pharmaceutical industry is predicted to be at its highest with repercussions beyond
the country’s borders, due to Germany’s strategic importance in the European
market. This project aimed to identify the challenges and opportunities created for
the industry in terms of pricing and market access of innovative pharmaceuticals.
METHODS: The impact was measured from three angles by developing hypotheses
and testing them thanks to a series of exploratory interviews with pharmaceutical
companies and Market access stakeholders. RESULTS: Results obtained project
that the impact of the reform for the industry will be very high, increasing the
importance of national stakeholders, altering the cost, time and strategy for mar-
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